Sponsor

Fate Therapeutics

Clinical research sponsor

Published trials9

Recruiting shown2

Roles1

SourceClinicalTrials.gov

Clinical trials

9 shown

FT839 in Autoimmune DiseasesNCT07800871 · lead sponsor · 2026-10-01

RECRUITING

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsNCT07216105 · lead sponsor · 2025-11-04

RECRUITING

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsNCT05395052 · lead sponsor · 2022-05-31

TERMINATED

FT538 in Combination With Monoclonal Antibodies in Advanced Solid TumorsNCT05069935 · lead sponsor · 2021-10-15

TERMINATED

FT516 in Combination With Monoclonal Antibodies in Advanced Solid TumorsNCT04551885 · lead sponsor · 2020-09-07

TERMINATED

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyNCT04106167 · lead sponsor · 2019-06-11

TERMINATED

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsNCT03841110 · lead sponsor · 2019-02-15

COMPLETED

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid TumorsNCT03319459 · lead sponsor · 2018-01-18

COMPLETED

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic MalignanciesNCT02743351 · lead sponsor · 2016-12-20

COMPLETED

Sponsor roles

lead sponsor9

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.